Profund Advisors LLC Buys 17,501 Shares of Scholar Rock Holding Corporation $SRRK

Profund Advisors LLC grew its stake in Scholar Rock Holding Corporation (NASDAQ:SRRK) by 57.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 48,152 shares of the company’s stock after acquiring an additional 17,501 shares during the period. Profund Advisors LLC’s holdings in Scholar Rock were worth $2,121,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of SRRK. AQR Capital Management LLC raised its stake in shares of Scholar Rock by 609.3% in the first quarter. AQR Capital Management LLC now owns 57,294 shares of the company’s stock worth $1,842,000 after acquiring an additional 49,217 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Scholar Rock by 12.3% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 53,046 shares of the company’s stock worth $1,709,000 after acquiring an additional 5,831 shares during the last quarter. Millennium Management LLC raised its stake in shares of Scholar Rock by 37.4% in the first quarter. Millennium Management LLC now owns 200,255 shares of the company’s stock worth $6,438,000 after acquiring an additional 54,555 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in shares of Scholar Rock by 25.6% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 169,825 shares of the company’s stock worth $5,460,000 after acquiring an additional 34,594 shares during the last quarter. Finally, Strs Ohio bought a new position in shares of Scholar Rock in the first quarter worth about $77,000. 91.08% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

SRRK has been the subject of a number of research analyst reports. Barclays boosted their target price on shares of Scholar Rock from $53.00 to $55.00 and gave the stock an “overweight” rating in a research note on Friday, May 8th. Piper Sandler boosted their price target on shares of Scholar Rock from $51.00 to $58.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 4th. Citigroup boosted their price target on shares of Scholar Rock from $55.00 to $58.00 and gave the stock a “buy” rating in a research note on Wednesday, March 4th. Raymond James Financial reissued a “strong-buy” rating on shares of Scholar Rock in a research note on Tuesday, March 3rd. Finally, HC Wainwright boosted their price target on shares of Scholar Rock from $58.00 to $65.00 and gave the stock a “buy” rating in a research note on Friday, May 8th. Five investment analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Scholar Rock currently has a consensus rating of “Buy” and a consensus target price of $56.00.

Insider Activity

In related news, insider Akshay Vaishnaw sold 12,246 shares of the business’s stock in a transaction that occurred on Thursday, April 16th. The shares were sold at an average price of $49.57, for a total transaction of $607,034.22. Following the completion of the transaction, the insider owned 630,542 shares in the company, valued at approximately $31,255,966.94. The trade was a 1.91% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Vikas Sinha sold 10,410 shares of the company’s stock in a transaction that occurred on Thursday, April 16th. The shares were sold at an average price of $49.57, for a total transaction of $516,023.70. Following the completion of the transaction, the chief financial officer owned 619,856 shares of the company’s stock, valued at $30,726,261.92. This trade represents a 1.65% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders have sold 71,975 shares of company stock valued at $3,546,591. 13.30% of the stock is currently owned by company insiders.

Scholar Rock Trading Up 0.4%

SRRK opened at $47.56 on Wednesday. The company has a market cap of $5.70 billion, a price-to-earnings ratio of -13.25 and a beta of 0.70. The firm has a 50 day simple moving average of $46.73 and a 200 day simple moving average of $44.12. The company has a debt-to-equity ratio of 0.71, a current ratio of 8.64 and a quick ratio of 8.64. Scholar Rock Holding Corporation has a fifty-two week low of $27.07 and a fifty-two week high of $51.63.

Scholar Rock (NASDAQ:SRRK) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.83) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.01). During the same quarter in the previous year, the business posted ($0.67) EPS. On average, sell-side analysts anticipate that Scholar Rock Holding Corporation will post -3.18 earnings per share for the current year.

Scholar Rock Profile

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).